Since its founding in 1994, the Case Western Reserve University/University Hospitals Case Medical Center (UHCMC) Center for AIDS Research (CWRU/UH CFAR) has been a source of excellence for both clinical and basic AIDS research. The CWRU/UH CFAR currently has 102 Full Members, 53 Associate CFAR members, who are students, postdoctoral fellows and research associates, and 21 International Members. Members are drawn from the CWRU School of Medicine, UHCMC, MetroHealth Medical Center, the Cleveland Clinic Foundation, the Louis Stokes Cleveland Veterans Administration Medical Center and the Joint Clinical Research Center (JCRC) in Kampala Uganda. Major strengths in the CWRU/UH CFAR include international research based on our 26-year research collaboration with Uganda, immune pathogenesis, basic virology and Cure research, and clinical trials. The CWRU/UH CFAR has the following Specific Aims: Provide scientific and administrative leadership to position the CWRU/UH CFAR at the forefront of HIV research (Administrative Core A). Conduct a responsive pilot grants program that accelerates junior faculty development and support for the next generation of HIV investigators (Developmental Core B). Support cutting edge research in Uganda by leveraging expertise from all CFAR Cores and programs (Uganda Laboratory Core C). As the first CFAR to make a major investment in international research, the CFAR operates one of the most advanced scientific laboratories in Sub-Saharan Africa. Support translational research through access to unique clinical specimens (Clinical Services Core D). Maintain a research infrastructure to support innovative multidisciplinary HIV research (Virology, Next Generation Sequencing and Imaging Core E, Immune Function Core F, Proteomics and Systems Biology Core G). To inform and engage CFAR and community members in our basic and clinical research programs and provide training, especially for minorities (Administrative Core A and Developmental Core B). Promote the national CFAR agenda by participating in collaborative research programs and assuming leadership in CFAR initiatives (Administrative Core A). In summary, through its scientific leadership, mentoring, pilot funding, scientific Cores, community outreach, and unique program in Uganda, the CFAR has effectively positioned its investigators at the leading edge of HIV/AIDS research. Although we remain relatively small, even as a tier-three CFAR we have been able to offer a range of Core services and activities that rival and often exceed those of much larger CFARs at other institutions.

Public Health Relevance

The HIV/AIDS pandemic is the single largest threat to global public health. The Case CFAR creates a collaborative environment that strongly supports HIV research at CWRU and for our colleagues working in Uganda and in other CFARs in the national network.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Center Core Grants (P30)
Project #
2P30AI036219-21
Application #
8899003
Study Section
Special Emphasis Panel (ZAI1)
Program Officer
Beaubien, Candice M
Project Start
1997-04-01
Project End
2020-04-30
Budget Start
2015-05-01
Budget End
2016-04-30
Support Year
21
Fiscal Year
2015
Total Cost
Indirect Cost
Name
Case Western Reserve University
Department
Biochemistry
Type
Schools of Medicine
DUNS #
077758407
City
Cleveland
State
OH
Country
United States
Zip Code
44106
Bengtson, Angela M; Pence, Brian W; Eaton, Ellen F et al. (2018) Patterns of efavirenz use as first-line antiretroviral therapy in the United States: 1999-2015. Antivir Ther 23:363-372
Tomalka, Amanda G; Resto-Garay, Ivelisse; Campbell, Kerry S et al. (2018) In vitro Evidence That Combination Therapy With CD16-Bearing NK-92 Cells and FDA-Approved Alefacept Can Selectively Target the Latent HIV Reservoir in CD4+ CD2hi Memory T Cells. Front Immunol 9:2552
Kalayjian, Robert C; Albert, Jeffrey M; Cremers, Serge et al. (2018) Women have enhanced bone loss associated with phosphaturia and CD4+ cell restoration during initial antiretroviral therapy. AIDS 32:2517-2524
AIDS-defining Cancer Project Working Group of IeDEA, COHERE in EuroCoord (2018) Non-Hodgkin lymphoma risk in adults living with HIV across five continents. AIDS 32:2777-2786
Mbonye, Uri; Wang, Benlian; Gokulrangan, Giridharan et al. (2018) Cyclin-dependent kinase 7 (CDK7)-mediated phosphorylation of the CDK9 activation loop promotes P-TEFb assembly with Tat and proviral HIV reactivation. J Biol Chem 293:10009-10025
Sayin, Ismail; Radtke, Andrea J; Vella, Laura A et al. (2018) Spatial distribution and function of T follicular regulatory cells in human lymph nodes. J Exp Med 215:1531-1542
Elion, Richard A; Althoff, Keri N; Zhang, Jinbing et al. (2018) Recent Abacavir Use Increases Risk of Type 1 and Type 2 Myocardial Infarctions Among Adults With HIV. J Acquir Immune Defic Syndr 78:62-72
Martinez, Leonardo; Shen, Ye; Handel, Andreas et al. (2018) Effectiveness of WHO's pragmatic screening algorithm for child contacts of tuberculosis cases in resource-constrained settings: a prospective cohort study in Uganda. Lancet Respir Med 6:276-286
Grover, Surbhi; Desir, Fidel; Jing, Yuezhou et al. (2018) Reduced Cancer Survival Among Adults With HIV and AIDS-Defining Illnesses Despite No Difference in Cancer Stage at Diagnosis. J Acquir Immune Defic Syndr 79:421-429
Kityo, Cissy; Makamdop, Krystelle Nganou; Rothenberger, Meghan et al. (2018) Lymphoid tissue fibrosis is associated with impaired vaccine responses. J Clin Invest 128:2763-2773

Showing the most recent 10 out of 539 publications